Download
fimmu-11-01782.pdf 292,54KB
WeightNameValue
1000 Titel
  • Could the Induction of Trained Immunity by β-Glucan Serve as a Defense Against COVID-19?
1000 Autor/in
  1. Geller, Anne |
  2. Yan, Jun |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-07-14
1000 Erschienen in
1000 Quellenangabe
  • 11:1782
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2020.01782 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372085/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • As the SARS-CoV-2 virus wreaks havoc on the populations, health care infrastructures and economies of nations around the world, finding ways to protect health care workers and bolster immune responses in the general population while we await an effective vaccine will be the difference between life and death for many people. Recent studies show that innate immune populations may possess a form of memory, termed Trained Immunity (TRIM), where innate immune cells undergo metabolic, mitochondrial, and epigenetic reprogramming following exposure to an initial stimulus that results in a memory phenotype of enhanced immune responses when exposed to a secondary, heterologous, stimulus. Throughout the literature, it has been shown that the induction of TRIM using such inducers as the BCG vaccine and β-glucan can provide protection through altered immune responses against a range of viral infections. Here we hypothesize a potential role for β-glucan in decreasing worldwide morbidity and mortality due to COVID-19, and posit several ideas as to how TRIM may actually shape the observed epidemiological phenomena related to COVID-19. We also evaluate the potential effects of β-glucan in relation to the immune dysregulation and cytokine storm observed in COVID-19. Ultimately, we hypothesize that the use of oral β-glucan in a prophylactic setting could be an effective way to boost immune responses and abrogate symptoms in COVID-19, though clinical trials are necessary to confirm the efficacy of this treatment and to further examine differential effects of β-glucan's from various sources.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal β-glucan
lokal trained immunity
lokal innate immunity
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R2VsbGVyLCBBbm5l|https://frl.publisso.de/adhoc/uri/WWFuLCBKdW4=
1000 Label
1000 Förderer
  1. National Institutes of Health |
1000 Fördernummer
  1. R01CA213990; P01CA163223
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer R01CA213990; P01CA163223
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6428054.rdf
1000 Erstellt am 2021-06-08T17:57:44.607+0200
1000 Erstellt von 218
1000 beschreibt frl:6428054
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet Tue Aug 30 09:54:50 CEST 2022
1000 Objekt bearb. Tue Aug 30 09:53:59 CEST 2022
1000 Vgl. frl:6428054
1000 Oai Id
  1. oai:frl.publisso.de:frl:6428054 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source